clock.bio Company Profile

Background

Mission and Vision

clock.bio is dedicated to extending human healthspan by developing innovative treatments aimed at preventing and addressing age-related diseases. The company focuses on decoding the rejuvenation programs inherent in human cells to reverse the detrimental effects of aging.

Primary Focus and Industry Significance

Operating within the biotechnology sector, clock.bio leverages the regenerative capabilities of human pluripotent stem cells (hiPSCs) to combat cellular aging. By harnessing these cells' unique ability to rejuvenate, the company aims to pioneer therapies that enhance quality of life and address the challenges posed by an aging population.

Key Strategic Focus

Core Objectives

• Decoding Rejuvenation Mechanisms: Identify and understand the genetic factors that enable cellular rejuvenation.

• Therapeutic Development: Translate these insights into clinical applications targeting age-related diseases.

Areas of Specialization

• Aging Models: Develop proprietary models that induce aging in hiPSCs to study rejuvenation processes.

• Genomic Screening: Utilize genome-wide CRISPR screens to identify genes involved in cellular rejuvenation.

Key Technologies Utilized

• CRISPR Screening: Conduct unbiased, comprehensive genome-wide screens to uncover rejuvenation-related genes.

• Single-Cell RNA Sequencing: Analyze gene expression at the single-cell level to understand rejuvenation pathways.

Primary Markets Targeted

• Age-Related Diseases: Focus on conditions such as neurodegenerative diseases, cardiovascular diseases, and other ailments prevalent in aging populations.

Financials and Funding

Funding History

• August 2023: Raised $4 million in venture equity from private investors.

• October 2024: Secured $5.3 million in seed funding led by LocalGlobe, with participation from BlueYard Capital, Onsight Ventures, and Dr. Jonathan Milner.

Utilization of Capital

• Atlas of Rejuvenation Factors: Developed a comprehensive database identifying over 100 genes associated with cellular rejuvenation.

• Validation and Target Prioritization: Focused on validating identified genes in somatic cells and mapping them to specific disease indications.

Pipeline Development

Key Pipeline Candidates

• Rejuvenation Gene Targets: Over 100 genes identified as potential targets for therapies aimed at reversing aging hallmarks.

Stages of Development

• Discovery Phase: Completion of genome-wide CRISPR screens and single-cell RNA sequencing to identify rejuvenation factors.

• Validation Phase: Ongoing validation of gene targets in somatic cells and analysis of associated pathways.

Target Conditions

• Age-Related Diseases: Neurodegenerative disorders, cardiovascular diseases, and other conditions linked to aging.

Anticipated Milestones

• Clinical Trials: Plans to initiate clinical trials by the end of the decade, aiming to extend human healthspan by 20 years based on biomarkers of aging.

Technological Platform and Innovation

Proprietary Technologies

• Aging Model in hiPSCs: Developed a model that induces aging in human induced pluripotent stem cells, faithfully recreating cellular hallmarks of aging.

Significant Scientific Methods

• Genome-Wide CRISPR Screens: Employed to identify genes causally relevant for cell rejuvenation.

• Single-Cell RNA Sequencing: Utilized to analyze gene expression profiles and understand rejuvenation pathways.

Leadership Team

• Markus Gstöttner, CEO: Co-founder of Meatable, with a background in public service, management consulting at McKinsey, and development economics.

• Dr. Rodrigo Santos, CTO: Former Director of Cell Technologies at Mogrify Ltd and Head of Technology at bit.bio, with extensive experience in cell technology development.

• Dr. Mark Kotter, Chairman and Co-founder: Stem cell biologist and neurosurgeon at the University of Cambridge, founder of bit.bio and co-founder of Meatable.

• Dr. Koby Baranes, Head of Science: Neuroscientist with over 13 years of experience, developed an aging model in human iPSCs during postdoctoral research at the University of Cambridge.

• Dr. Grant Belgard, Adviser (Bioinformatics): Computational biologist and entrepreneur, Senior Director of Bioinformatics at bit.bio, and founder of The Bioinformatics CRO.

• Dr. Tilmann Bürckstümmer, Adviser (CRISPR): Biochemist and CRISPR expert, co-founder of Myllia Biotechnology, and CEO of bit.bio discovery.

• Dr. Fabio D’Orazio, Lead Bioinformatician: Bioinformatician with expertise in epigenetics and next-generation sequencing, former Marie-Curie fellow and postdoc at Imperial College London.

• Dr. Joana Tavares, Head of Target Validation: Scientist with a background in bioengineering and neuroscience, PhD from the University of Cambridge, focusing on cellular metabolism and myelin formation.

• Dr. Elena Patili, Scientist: Geneticist with experience in target and pathway validation at GSK, PhD in Neurogenetics from the University of Cambridge.

• Dr. Janine Brandes, Research Scientist: Neuroscientist with a PhD from the University of Cambridge, developed novel human 3D cell models to investigate immune-brain interactions.

• Jack, Senior Scientist: Post-doctoral scientist with over a decade of experience in neurodegeneration and inflammation, PhD from University College London, former fellow at Alzheimer’s Research UK.

• Lorraine Stephens, Chief of Staff: Leads operations across finance, HR, and recruitment, with a background in retail banking and biotech industry operations.

Leadership Changes

• 2024 Appointments:

• CEO: Markus Gstöttner

• CTO: Dr. Rodrigo Santos

Competitor Profile

Market Insights and Dynamics

• Market Size and Growth Potential: The global anti-aging market is experiencing significant growth, driven by increasing life expectancy and a rising prevalence of age-related diseases.

• Industry Trends: Advancements in biotechnology, particularly in stem cell research and gene therapy, are opening new avenues for age-related disease treatment.

Competitor Analysis

• Broken String Biosciences: Focuses on genomic integrity and stability, with an estimated revenue of $4.2 million and 54 employees.

• Enhanc3D Genomics: Specializes in 3D genomics to understand gene regulation, with an estimated revenue of $2.7 million and 35 employees.

• Dunad Therapeutics: Develops covalent small molecule therapies, with an estimated revenue of $3.3 million and 43 employees.

• Maxion Therapeutics: Focuses on antibody-based therapeutics, with an estimated revenue of $3.3 million and 43 employees.

• Camena Bioscience: Works on synthetic biology and gene synthesis, with an estimated revenue of $2.9 million and 38 employees.

• Spirea: Develops antibody-drug conjugates, with an estimated revenue of $0.9 million and 12 employees.

Strategic Collaborations and Partnerships

• Milner Therapeutics Institute: Located within this institute at the University of Cambridge, providing access to cutting-edge research facilities and collaboration opportunities.

Operational Insights

• Competitive Advantages:

• Proprietary Aging Model: Ability to induce aging in hiPSCs and study rejuvenation mechanisms.

• Comprehensive Genomic Screening: Utilization of genome-wide CRISPR screens and single-cell RNA sequencing to identify rejuvenation factors.

• Market Position: Positioned at the forefront of aging research, with a focus on translating scientific discoveries into clinical applications.

Strategic Opportunities and Future Directions

• Clinical Translation: Advance identified rejuvenation factors into therapeutic candidates for age-related diseases.

• Partnerships: Seek collaborations with pharmaceutical companies to accelerate clinical development and commercialization.

• Expansion: Broaden research into other aspects of aging and related conditions to diversify the therapeutic pipeline.

Contact Information

• Website: clock.bio

• LinkedIn: clock.bio LinkedIn

• Twitter: @clockbio